Abeona Therapeutics Inc
ABEO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$249.32M
Close$
$0.28
93.3% downside
Current Fair Value
93.3% downsideOvervalued by 93.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $249.32 Million |
|---|---|
| Enterprise Value | $212.97 Million |
| Earnings per Share | $1.34 |
| Beta | 1.3 |
| Outstanding Shares | 57,048,385 |
Return
| Return on Equity | -49.11% |
|---|---|
| Return on Assets | -35.03% |
| Return on Invested Capital | -159.18% |
Valuation & Multiples
| P/E Ratio | -3.83 |
|---|---|
| PEG | 3.23 |
| Price to Sales | - |
| Price to Book Ratio | 2.11 |
| Enterprise Value to Revenue | 8.35 |
| Enterprise Value to EBIT | -0.86 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.23
Consensus analyst estimateRevenue Estimate
$12.24 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.14
Consensus analyst estimateRevenue Estimate
$14.82 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Abeona Therapeutics Inc
226 employees
CEO: Joao Siffert
Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a pers...